

Curriculum Vitae

Richard Y. Lam

4676 Admiralty Way, Suite 101
Marina del Rey, CA 90292
T: 310 827 7707
E: richard@prostateoncology.com

DEA: BL5206190
CA License: A60442
NPI: 1811925258

Education

Undergraduate	University of California, Los Angeles Bachelor of Science, Biology. June 1990
Graduate	University of California, Los Angeles Doctor of Medicine. June 1994

Postdoctoral Training

Internship	University of California, Los Angeles Center of Health Sciences Department of Internal Medicine. 1994-95
Residency	University of California, Los Angeles Center of Health Sciences Department of Internal Medicine. 1995-97
Fellowship	University of California, Los Angeles Harbor-UCLA Hospital Department of Internal Medicine Division of Medical Oncology and Hematology. 1998-2001

Work Experience

Kaiser Foundation Hospital of West Los Angeles
Medical Emergency Room and Urgent Care Center
Physician, 1997-98

Prostate Oncology Specialists
Oncology Specialist, Research Director 2001-present

Certification and Licensure

United States Medical Licensing Examination, Steps 1-3, 1992-95
California Physicians and Surgeons License, 1996
Diplomat, American Board of Internal Medicine, 1997
Diplomat, American Board of Internal Medicine (Oncology), 2001

Honors and Awards

Phi Beta Sigma National Honor Society, UCLA, 1987
Outstanding Students of America Award, UCLA, 1987
Golden Key National Honor Society, UCLA, 1988
Graduated magna cum laude, UCLA, 1990
Phi Beta Kappa, UCLA, 1990
Western AUA, Best Abstract - First runner up, 2003
Prostate Cancer Research Institute, Annual Meeting Best Speaker, 2006
Southern California Super Doctors, 2008-2018.

Memberships

American Society of Hematology
American Society of Clinical Oncology
Cancer Committee, Daniel Freeman Memorial Hospital
Medical Advisory Board, Prostate Cancer Research Institute

Speaker Bureaus

Pfizer Corporation
Sanofi Aventis Corporation
Janssen Pharmaceuticals

Clinical Trials for Prostate Cancer

1. 212082PCR3001: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed after Taxane-based Chemotherapy
2. 9785-CL-0401: A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
3. Addition of Bevacizumab to Taxanes Restores Anti-cancer Efficacy of Taxanes in Taxane-Refractory Prostate Cancer
4. Androgen Replacement for Prostate Cancer Patients with Testicular Failure
5. BMS184-043: A Randomized, Double-blind, Phase III Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that Have Received Prior Treatment with Docetaxel
6. BMS184-095: A Randomized, Double-blind, Phase III Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
7. COU-AA-301: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
8. COU-AA-302: A Phase III, Randomized, Double-blind, Placebo-controlled study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
9. CRPC2: A Multinational Phase III, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
10. GU 115/I6A-MC-CBBB: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of

Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

11. Lack of Benefit of Local Therapy for Men with Preexisting AIPC
12. OGX-011-11: A Randomized Phase III Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custersin (OGX-011) in Men with Metastatic Castrate-Resistant Prostate Cancer
13. OGX-011-12: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
14. ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer in the United States
15. P10-3 PROCEED: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
16. P11-3: A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
17. P11-4 PRIME: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
18. P12-1: A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
19. Prevention of Gynecomastia with an Aromatase Inhibitor Femara
20. PROCEDE-1000: An Open Registry to Measure the Impact of Adding Genomic Testing (Polaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
21. Prognostic Significance of Negative Biopsy after 12 Months of Hormone Blockade
22. SIPIPI 2013: Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
23. Testosterone Replacement for Hypogonadal Men with Treated Prostate Cancer
24. The Effect of Finasteride on Prolonging Time Off in Patients on Intermittent Hormone Blockade
25. The Prevention of Bone Loss with Oral Bisphosphonates
26. TOK-200-15: A Phase 3, Randomized, Open Label, Multicenter, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
27. XL184-306: A Phase III, Randomized, Double-blind, Controlled Trial of Cabzantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer
28. CO39385: A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen.

29. GU 115 Eli Lilly: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer.
30. ONC-MA-1004 TRUMPET: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States.
31. ROSSER 2015-4: Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer.

Publications

Lam, R., and R. Chlebowski. "Tamoxifen to Treat Premenopausal Women with Breast Cancer." *Cancer Investigation* 18 (2000): 681-684.

Curti, Mario, Millie Leung, Richard Lam, Sohail Saeed, Priya Gulati, and Yutaka Niihara. "Successful Treatment of a Patient with Pure Red Cell Aplasia with Prednisone, Cyclosporine and Antithymocyte Globulin." *Medicine of the Americas* 2, no. 2 (2001): 139-139.

Scholz, M., R. Lam, and B. Guess. "Anti-androgen Monotherapy for Prostate-Cancer." *PAACT* 18, no. 2 (2002).

Scholz, M., R. Lam, S. Brosman, and B. Guess. "Calcitriol restores docetaxel anticancer activity in men with androgen independent prostate cancer who previously progressed on docetaxel." *Proc West AUA* (2003).

Cone, Lawrence A., Millie M. Leung, Richard G. Byrd, Gary M. Annunziata, Richard Y. Lam, and Brian K. Herman. "Multiple cerebral abscesses because of *Listeria monocytogenes*: three case reports and a literature review of supratentorial listerial brain abscess (es)." *Surgical neurology* 59, no. 4 (2003): 320-328.

Scholz, M., R. Lam, S. Brosman, and B. Guess. "Extent of disease on bone scan, baseline alkaline phosphatase, and 80% decline in PSA are the best indicators predicting long-term survival in men with androgen independent prostate cancer treated with ketoconazole." *Proc West AUA* (2003).

Scholz, M., T. Trilling, S. Brosman, B. Guess, H. Johnson, and R. Lam. "PSA nadir greater than 0.1 on combined hormone blockade predicts the early development of androgen independent prostate cancer in men with PSA relapse after local therapy." *Proc West AUA* (2003).

Guess, B. W., M. C. Scholz, S. B. Strum, R. Y. Lam, H. J. Johnson, and R. I. Jennrich. "Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study." *Prostate cancer and Prostatic Diseases* 6, no. 4 (2003): 301-304.

Lam, R. Y., M. Scholz, B. Guess, J. Mahoney, H. Johnson, T. Trilling, and H. Goodman. "Oral bisphosphonates for the prevention of androgen deprivation therapy-associated bone loss-Preliminary findings." In *ASCO Annual Meeting Proceedings*, vol. 22, no. 14_suppl, p. 4749. 2004.

Scholz, Mark, Robert Jennrich, Stephen Strum, Stanley Brosman, Henry Johnson, and Richard Lam. "Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone." *The Journal of Urology* 173, no. 6 (2005): 1947-1952.

Scholz, M., R. Lam, B. Guess, and R. Blum. "When Should You Start Treatment with Ketoconazole?" *PAACT* 21, no. 4 (2005).

*Scholz, M., R. Lam, S. Strum, H. Johnson, T. Trilling, and R. Jennrich. "Intermittent Use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during Testosterone-Recovery Prolongs the Time-Off-Period." Abstract. *Multidisciplinary Prostate Cancer Symposium* (2005): 153.

Lam, R., M. Scholz, B. Guess, and T. Trilling. "Oral Bisphosphonates Fail to Prevent Bone Loss from Androgen Deprivation Therapy in Men with Prostate Cancer." ASCO Multidisciplinary Prostate Conference, 2006.

Scholz, Mark C., Robert I. Jennrich, Stephen B. Strum, Henry J. Johnson, Brad W. Guess, and Richard Y. Lam. "Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period." *The Journal of Urology* 175, no. 5 (2006): 1673-1678.

Guess, Brad W., Mark C. Scholz, and Richard Y. Lam. "Preventing and treating the side effects of testosterone inactivating pharmaceuticals in men with prostate cancer." In *Seminars in Preventive and Alternative Medicine*, vol. 2, no. 2, (2006): 76-84.

Scholz, M. C., R. Lam, B. Guess, S. Strum, H. Johnson, and R. Jennrich. "Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression." In *ASCO Annual Meeting Proceedings*, vol. 24, no. 18_suppl, p. 14531. 2006.

Porter, Michael P. "Outcomes of treatment vs observation of localized prostate cancer in elderly men." *Jama* 297, no. 15 (2007): 1651-1653.

Scholz, M., Bahn, D., and Lam, R., "Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it Foolproof?" *PCRI Insights* 10, no. 1 (2007).

*Scholz, Mark, Richard Lam, Stephen Strum, Robert Jennrich, Henry Johnson, and Tom Trilling. "Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals." *Urology* 70, no. 3 (2007): 506-510.

Scholz, M., R. Lam, S. Strum, and H. Johnson. "Active Surveillance after Induction with Testosterone Inactivating Pharmaceuticals (TIP): Ten Year Outcome." Abstract. *Active Surveillance Symposium* 10 (2007).

Scholz, M., Lam, R., and Mendenhall, M. "My Doc Personalized Patient Information", *Novartis Oncology*, DVD. USA: Novartis, 2009.

Lam, R., "High Dose Ketoconazole Plus Hydrocortisone (HDK+HC)." *PAACT, Inc. Prostate Cancer Communication Newsletter* 26, no 3 (2010).

Scholz, Mark C., Richard Y. Lam, Stephen B. Strum, Dean J. LaBarba, Lauren K. Becker, Patricia Chang, Nojan Farhoumand, and Robert I. Jennrich. "Primary intermittent androgen deprivation as initial therapy for

men with newly diagnosed prostate cancer." *Clinical Genitourinary Cancer* 9, no. 2 (2011): 89-94.

Lam, R., "Experience with sipuleucel-t (Sip-T) in a community oncology clinic: Initial 50 patients." Abstract. ASCO-GU (2012).

Scholz, Mark C., Meg K. Groom, Andrew J. Kaddis, Stephen B. Strum, Robert I. Jennrich, Duke K. Bahn, Patricia J. Chang, Lauren K. Becker, and Richard Y. Lam. "Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): a retrospective study." *The Prostate* 73, no. 1 (2013): 83-88.

Scholz, M., R. Lam, J. Turner, and C.U. Felarca. "Y-90 resin in castrate-resistant prostate cancer with liver metastasis." Abstract. ASCO Gastrointestinal Cancers Symposium (2016).

Scholz, M., S. Yep, C. Kelly, K.N. Chau, J. Turner, and R. Lam. "Phase I trial of sipuleucel-T combined with ipilimumab (SIPIT) in progressive M-CRPC." Abstract. ASCO (2016).

Scholz, M., R. Lam, and J. Turner. "Sir-Spheres (SS) for prostate cancer (PC) metastatic to liver." Abstract. Genitourinary Cancers Symposium (2016).

Lectures

Tumor Board (Presenter and Discussant) Kaiser Permanente Bellflower. Weekly from October 1999 to April 2000 and November 2000 to February 2001.

"Promising Experimental Drugs in Prostate Cancer." Prostate Cancer Patient Support Group, Marina del Rey. November 2001.

"Treatment Options for the Newly Diagnosed Prostate Cancer Patient." Physician Education Lecture, Daniel Freeman Medical Center. April 4, 2002.

"Ketoconazole for Androgen Independent Prostate Cancer." National Conference on Prostate Cancer, University of Southern California. October 4, 2002.

"Management of Relapsed Prostate Cancer," Prostate Cancer Patient Support Group, Mercy Hospital of Bakersfield. April 1, 2003.

"Medical Options for Relapsed Prostate Cancer." Prostate Cancer Patient Support Group, Holy Cross Medical Center. July 15, 2003.

"Nizoral-Promising Results for a Treatment Often Overlooked." National Conference on Prostate Cancer, Burbank Hilton Convention Center. September 7, 2003.

"Management of Toxicities Related to Androgen Deprivation Therapy." Southern California Radiological Society. January 23, 2004.

"Approach to a Newly Diagnosed Prostate Cancer Patient." Wellness Community, Santa Monica, California. February 9, 2004.

"Management of Toxicities Related to Androgen Deprivation Therapy." Prostate Cancer Support Group, Marina del Rey. February 19, 2004.

"Approach to a Newly Diagnosed Prostate Cancer Patient." US Too Prostate Support Group, Las Vegas, June 17, 2004.

"The Indications and Side Effects of Hormone Blockade." Man-2-Man Prostate Support Group. Anaheim Memorial Hospital. July 7, 2004.

"Tailoring Therapy for the Newly Diagnosed Patient." Prostate Cancer Support Group, Marina del Rey. August 12, 2004.

"Treatment Options for Relapsed Prostate Cancer." US-Too, Phoenix. October 23, 2004.

"New Options for Prostate Cancer." Wellness Community, Santa Monica, November 8, 2004.

"Management of Relapsed Prostate Cancer." COPE-Support Group, Huntington Hospital. December 2, 2004.

"Prostate Cancer Update." Physician CME Lecture. Daniel Freeman Marina Hospital, May 6, 2005.

"Hormone Resistant Prostate Cancer." Wellness Community Westlake. May 21, 2005.

"Novel Therapies in Prostate Cancer." Southwestern Prostate Health Conference, Phoenix. September 17, 2005.

"New Treatment Options for Prostate Cancer." Los Robles Community Hospital. November 2, 2005.

"Systemic Therapies for Prostate Cancer." COPE-Support Group, Huntington Hospital. February 6, 2006.

"Addressing the Side Effects of Testosterone Inactivating Pharmaceuticals." Prostate Cancer Research Institute Annual Conference, Cal State University Los Angeles. Sept 9, 2006.

"Novel Therapies in Prostate Cancer." Prostate Cancer Education and Awareness Conference. Southwestern University, Phoenix. Oct 28, 2006.

"Role of Taxotere in Prostate Cancer." Prostate Cancer Research Institute Annual Conference, Los Angeles. Sept 8, 2007.

"What's New in Prostate Cancer Management in 2008." US-Too, Las Vegas. Jan 18, 2008.

"Active Surveillance: A Safe and Logical Choice. Role of the Color Doppler Ultrasound." The Informed Prostate Cancer Support Group, Moores Cancer Center, July 18, 2008.

"Chemotherapy in Prostate Cancer." Prostate Cancer Research Institute Annual Conference, Los Angeles. Sept 10, 2008.

"Update on New Developments in Prostate Cancer: 2009," Wellness Community, Santa Monica, June 9, 2009.

"Prostate Cancer Breakthroughs in 2009." US-Too/American Cancer Society, Westlake Village, June 17, 2009.

"What's New in For Prostate Cancer in 2009." The Informed Prostate Cancer Support Group, Moores Cancer Center, August 15, 2009.

"Role of Chemotherapy in Prostate Cancer," Prostate Cancer Research Institute Annual Conference, Los Angeles. September, 2009.

"Management of Hormone Refractory Advanced Prostate Cancer." The Prostate Forum of Orange County, January 10, 2010.

"The Ins and Outs of Androgen Deprivation Therapy," The Prostate Network Support Group, August 20, 2011.

"High Risk Prostate Cancer," Prostate Cancer Research Institute Annual Conference, Los Angeles. September, 2012.

"Prostate Cancer 101: From Evaluation to Treatment," The Informed Prostate Cancer Support Group, UCSD, May 18, 2013.

"Androgen Deprivation Therapy: The Androgen Receptor Makes a Comeback," The Informed Prostate Cancer Support Group, UCSD, Nov 15, 2014.

Television and Videos

"Auckland Teacher Faces Rare Cancer Rare Treatment", 3 news. 07 August 2013.

Speakers Bureau

Dendreon Corporation
Medivation Corporation
Janssen Pharmaceuticals